SLNCF
Silence Therapeutics plc
Price Chart
Latest Quote
$1.06
+0.00 (+0.00%)
Current Price
| Previous Close | $1.06 |
| Open | $2.00 |
| Day High | $2.21 |
| Day Low | $2.00 |
| Volume | 300 |
Stock Information
| Shares Outstanding | 141.70M |
| Total Debt | $136K |
| Cash Equivalents | $70.08M |
| Revenue | $839K |
| Net Income | $-75.04M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $150.21M |
| EPS (TTM) | $-1.13 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $243.22M |
| Sales | $839K |
| Income | $-75.04M |
| Book/sh | $0.35 |
| Cash/sh | $0.49 |
| Employees | 88 |
Financial Ratios
| Quick Ratio | 8.82 |
| Current Ratio | 9.83 |
| Debt/Eq | 0.28 |
Returns & Margins
| ROA | -29.79% |
| ROE | -92.56% |
| Gross Margin | 79.50% |
| Operating Margin | -3565.40% |
Ownership
| Insider Ownership | 8.76% |
| Institutional Ownership | 0.00% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 179.03 |
| P/B | 3.04 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.16 |
| SMA50 | $1.81 |
| SMA200 | $1.72 |
| RSI | 100.00 |
| ATR | 0.0821 |
| Shares Float | 74.75M |
| Rel Volume | 18.46 |
Performance History
| Week | +108.49% |
| Month | +52.15% |
| Quarter | +10.50% |
| 6 Months | +22.78% |
| YTD | +10.50% |
| Year | +47.33% |
| 3 Years | +67.42% |
| 5 Years | -74.74% |
| 10 Years | +16.32% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-15 | $2.21 | 2,400 |
| 2026-06-12 | $1.06 | 0 |
| 2026-06-11 | $1.06 | 0 |
| 2026-06-10 | $1.06 | 0 |
| 2026-06-09 | $1.06 | 0 |
| 2026-06-08 | $1.06 | 0 |
| 2026-06-05 | $1.06 | 0 |
| 2026-06-04 | $1.06 | 0 |
| 2026-06-03 | $1.06 | 0 |
| 2026-06-02 | $1.06 | 0 |
| 2026-06-01 | $1.06 | 0 |
| 2026-05-29 | $1.06 | 0 |
| 2026-05-28 | $1.06 | 0 |
| 2026-05-27 | $1.06 | 0 |
| 2026-05-26 | $1.06 | 0 |
| 2026-05-22 | $1.06 | 0 |
| 2026-05-21 | $1.06 | 0 |
| 2026-05-20 | $1.06 | 200 |
| 2026-05-19 | $1.45 | 0 |
| 2026-05-18 | $1.45 | 0 |
About Silence Therapeutics plc
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
đ° Latest News
This Silence Therapeutics Insider Increased Their Holding In The Last Year
Simply Wall St. âĸ 2026-05-12T10:07:35Z
Silence Therapeutics (SLN) Soars 19.0%: Is Further Upside Left in the Stock?
Zacks âĸ 2026-04-16T12:50:00Z
We Think Silence Therapeutics (NASDAQ:SLN) Needs To Drive Business Growth Carefully
Simply Wall St. âĸ 2026-04-01T10:16:31Z
European Equities Traded in the US as American Depositary Receipts Higher Monday
MT Newswires âĸ 2026-03-16T15:22:40ZEuropean Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading
MT Newswires âĸ 2026-03-10T15:10:20ZEuropean Equities Traded in the US as American Depositary Receipts Decline in Monday Trading
MT Newswires âĸ 2026-03-09T15:30:10ZWall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?
Zacks âĸ 2026-03-05T14:55:01Z
European Equities Traded in the US as American Depositary Receipts Tumble in Monday Trading
MT Newswires âĸ 2026-03-02T16:07:08ZSpotlight On Silence Therapeutics And 2 Other Promising Penny Stocks
Simply Wall St. âĸ 2026-02-19T12:05:06Z
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading; Little Changed for the Week
MT Newswires âĸ 2026-02-06T16:09:23Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $11,810,000 | $12,867,000 | $13,463,000 | $10,062,893 |
| Cost Of Revenue | $11,810,000 | $12,867,000 | $13,463,000 | $10,062,893 |
| Total Revenue | $43,258,000 | $31,643,000 | $21,655,000 | $16,755,743 |
| Operating Revenue | $43,258,000 | $31,643,000 | $21,655,000 | $16,755,743 |
| Expenses | ||||
| Total Expenses | $106,577,000 | $96,026,000 | $82,695,000 | $78,588,010 |
| Other Income Expense | $14,383,000 | $9,308,000 | $11,114,000 | $-59,384 |
| Other Non Operating Income Expenses | $13,737,000 | $11,949,000 | $9,820,000 | - |
| Net Non Operating Interest Income Expense | $4,472,000 | $1,803,000 | $280,000 | $2,699 |
| Operating Expense | $94,767,000 | $83,159,000 | $69,232,000 | $68,525,117 |
| Other Operating Expenses | $-13,737,000 | $-11,949,000 | $-9,820,000 | - |
| General And Administrative Expense | $26,884,000 | $26,222,000 | $25,682,000 | $27,003,536 |
| Interest Expense | - | $43,313 | $56,879 | $10,797 |
| Interest Expense Non Operating | - | $43,313 | $56,879 | $10,797 |
| Rent Expense Supplemental | - | - | $410,000 | $448,079 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-45,309,000 | $-54,228,000 | $-50,334,000 | $-53,189,192 |
| Net Interest Income | $4,472,000 | $1,803,000 | $280,000 | $2,699 |
| Interest Income | $4,472,000 | $1,803,000 | $280,000 | $13,496 |
| Normalized Income | $-45,793,500 | $-52,088,790 | $-51,382,140 | $-53,138,156 |
| Net Income From Continuing And Discontinued Operation | $-45,309,000 | $-54,228,000 | $-50,334,000 | $-53,189,192 |
| Total Operating Income As Reported | $-63,319,000 | $-64,383,000 | $-61,040,000 | $-61,832,267 |
| Net Income Common Stockholders | $-45,309,000 | $-54,228,000 | $-50,334,000 | $-53,189,192 |
| Net Income | $-45,309,000 | $-54,228,000 | $-50,334,000 | $-53,189,192 |
| Net Income Including Noncontrolling Interests | $-45,309,000 | $-54,228,000 | $-50,334,000 | $-53,189,192 |
| Net Income Continuous Operations | $-45,309,000 | $-54,228,000 | $-50,334,000 | $-53,189,192 |
| Pretax Income | $-44,464,000 | $-53,272,000 | $-49,646,000 | $-61,888,952 |
| Interest Income Non Operating | $4,472,000 | $1,803,000 | $280,000 | $13,496 |
| Operating Income | $-63,319,000 | $-64,383,000 | $-61,040,000 | $-61,832,267 |
| Gross Profit | $31,448,000 | $18,776,000 | $8,192,000 | $6,692,850 |
| Per Share | ||||
| Diluted EPS | $-0.33 | $-0.49 | $-0.52 | $-0.60 |
| Basic EPS | $-0.33 | $-0.49 | $-0.52 | $-0.60 |
| Other | ||||
| Tax Effect Of Unusual Items | $161,500 | $-501,790 | $245,860 | $-8,348 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-63,372,000 | $-61,121,000 | $-61,738,000 | $-61,242,476 |
| Total Unusual Items | $646,000 | $-2,641,000 | $1,294,000 | $-59,384 |
| Total Unusual Items Excluding Goodwill | $646,000 | $-2,641,000 | $1,294,000 | $-59,384 |
| Reconciled Depreciation | $593,000 | $621,000 | $596,000 | $576,295 |
| EBITDA (Bullshit earnings) | $-62,726,000 | $-63,762,000 | $-60,444,000 | $-61,301,860 |
| EBIT | $-63,319,000 | $-64,383,000 | $-61,040,000 | $-61,878,155 |
| Diluted Average Shares | $138,752,224 | $111,277,250 | $96,584,512 | $88,950,441 |
| Basic Average Shares | $138,752,224 | $111,277,250 | $96,584,512 | $88,950,441 |
| Diluted NI Availto Com Stockholders | $-45,309,000 | $-54,228,000 | $-50,334,000 | $-53,189,192 |
| Tax Provision | $845,000 | $956,000 | $688,000 | $-8,699,760 |
| Gain On Sale Of Security | $646,000 | $-2,641,000 | $1,294,000 | $-59,384 |
| Other Taxes | $-13,737,000 | $-11,949,000 | $-9,820,000 | - |
| Research And Development | $67,883,000 | $56,937,000 | $43,550,000 | $41,521,581 |
| Selling General And Administration | $26,884,000 | $26,222,000 | $25,682,000 | $27,003,536 |
| Other Gand A | $26,884,000 | $26,222,000 | $25,682,000 | $27,003,536 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $124,319,000 | $11,650,000 | $16,631,773 | $1,228,170 |
| Total Assets | $202,635,000 | $119,448,000 | $130,096,453 | $129,826,977 |
| Total Non Current Assets | $15,269,000 | $16,297,000 | $13,087,098 | $13,308,770 |
| Non Current Prepaid Assets | $3,234,000 | $3,284,000 | $0 | - |
| Goodwill And Other Intangible Assets | $9,704,000 | $10,343,000 | $10,079,752 | $10,278,835 |
| Other Intangible Assets | $312,000 | $362,000 | $387,264 | $32,391 |
| Current Assets | $187,366,000 | $103,151,000 | $117,009,355 | $116,518,207 |
| Prepaid Assets | $13,124,000 | $10,385,000 | $9,923,636 | $5,815,586 |
| Receivables | $26,908,000 | $23,977,000 | $20,987,281 | $11,454,369 |
| Other Receivables | $24,396,000 | $22,442,000 | - | - |
| Taxes Receivable | $1,540,000 | $1,245,000 | $19,879,948 | $11,007,639 |
| Accounts Receivable | $972,000 | $290,000 | $1,107,333 | $446,730 |
| Cash Cash Equivalents And Short Term Investments | $147,334,000 | $68,789,000 | $86,098,438 | $99,248,252 |
| Cash And Cash Equivalents | $121,330,000 | $68,789,000 | $66,338,299 | $99,248,252 |
| Cash Equivalents | $64,740,000 | $36,970,000 | $15,526,860 | $0 |
| Cash Financial | $56,590,000 | $31,819,000 | $50,811,439 | $99,248,252 |
| Investmentin Financial Assets | - | $361,788 | $343,697 | $406,241 |
| Debt | ||||
| Total Debt | $117,000 | $346,000 | $539,749 | $184,900 |
| Long Term Debt And Capital Lease Obligation | $0 | $118,000 | $0 | - |
| Current Debt And Capital Lease Obligation | $117,000 | $228,000 | $539,749 | $184,900 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $68,612,000 | $97,455,000 | $103,384,928 | $118,319,972 |
| Total Non Current Liabilities Net Minority Interest | $51,790,000 | $75,119,000 | $76,829,519 | $97,850,028 |
| Non Current Deferred Liabilities | $51,790,000 | $75,001,000 | $76,829,519 | $97,850,028 |
| Current Liabilities | $16,822,000 | $22,336,000 | $26,555,409 | $20,469,944 |
| Current Deferred Liabilities | $306,000 | $6,571,000 | $10,727,209 | $5,731,908 |
| Payables And Accrued Expenses | $12,954,000 | $12,403,000 | $15,288,451 | $14,553,135 |
| Payables | $4,593,000 | $4,556,000 | $5,133,667 | $6,165,142 |
| Total Tax Payable | $896,000 | $1,208,000 | $1,277,971 | $678,867 |
| Income Tax Payable | $652,000 | $474,000 | $712,808 | $249,683 |
| Accounts Payable | $3,697,000 | $3,348,000 | $3,855,696 | $5,486,274 |
| Equity | ||||
| Common Stock Equity | $134,023,000 | $21,993,000 | $26,711,525 | $11,507,005 |
| Total Equity Gross Minority Interest | $134,023,000 | $21,993,000 | $26,711,525 | $11,507,005 |
| Stockholders Equity | $134,023,000 | $21,993,000 | $26,711,525 | $11,507,005 |
| Gains Losses Not Affecting Retained Earnings | $-11,781,000 | $-10,725,000 | $29,447,786 | $32,106,513 |
| Other Equity Adjustments | $-11,781,000 | $-10,725,000 | $26,924,520 | $30,026,723 |
| Retained Earnings | $-474,044,000 | $-431,894,000 | $-318,600,767 | $-300,923,152 |
| Other Equity Interest | - | $44,433,687 | $28,739,819 | $18,473,831 |
| Other | ||||
| Ordinary Shares Number | $141,674,074 | $118,846,966 | $107,808,471 | $89,784,720 |
| Share Issued | $141,674,074 | $118,846,966 | $107,808,471 | $89,784,720 |
| Tangible Book Value | $124,319,000 | $11,650,000 | $16,631,773 | $1,228,170 |
| Invested Capital | $134,023,000 | $21,993,000 | $26,711,525 | $11,507,005 |
| Working Capital | $170,544,000 | $80,815,000 | $90,453,946 | $96,048,263 |
| Capital Lease Obligations | $117,000 | $346,000 | $539,749 | $184,900 |
| Total Capitalization | $134,023,000 | $21,993,000 | $26,711,525 | $11,507,005 |
| Additional Paid In Capital | $609,560,000 | $455,765,000 | $280,601,711 | $255,791,292 |
| Capital Stock | $10,288,000 | $8,847,000 | $6,522,976 | $6,058,520 |
| Common Stock | $10,288,000 | $8,847,000 | $6,522,976 | $6,058,520 |
| Non Current Deferred Revenue | $51,790,000 | $75,001,000 | $76,829,519 | $97,850,028 |
| Long Term Capital Lease Obligation | $0 | $118,000 | $0 | - |
| Current Deferred Revenue | $306,000 | $6,571,000 | $10,727,209 | $5,731,908 |
| Current Capital Lease Obligation | $117,000 | $228,000 | $539,749 | $184,900 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,445,000 | $3,134,000 | - | - |
| Current Accrued Expenses | $8,361,000 | $7,847,000 | $10,154,785 | $8,387,994 |
| Goodwill | $9,392,000 | $9,981,000 | $9,692,488 | $10,246,444 |
| Net PPE | $2,331,000 | $2,670,000 | $2,663,649 | $2,623,694 |
| Accumulated Depreciation | $-4,525,000 | $-4,498,000 | $-3,973,085 | $-4,741,275 |
| Gross PPE | $6,856,000 | $7,168,000 | $6,636,734 | $7,364,969 |
| Construction In Progress | $356,000 | $362,000 | - | - |
| Other Properties | $157,000 | $370,000 | $602,679 | $465,625 |
| Machinery Furniture Equipment | $6,343,000 | $6,436,000 | $6,034,055 | $6,899,344 |
| Other Short Term Investments | $26,004,000 | $0 | $19,760,138 | $0 |
| Foreign Currency Translation Adjustments | - | $2,485,382 | $2,523,266 | $2,079,791 |
| Investments And Advances | - | $361,788 | $343,697 | $406,241 |
| Available For Sale Securities | - | $361,788 | $343,697 | - |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-67,851,000 | $-49,518,000 | $-57,589,000 | $7,385,213 |
| Operating Activities | ||||
| Operating Cash Flow | $-67,640,000 | $-49,462,000 | $-57,044,000 | $9,185,629 |
| Cash Flow From Continuing Operating Activities | $-67,640,000 | $-49,462,000 | $-57,044,000 | $9,185,629 |
| Operating Gains Losses | $-2,581,000 | $3,962,000 | $-1,003,000 | $411,639 |
| Investing Activities | ||||
| Capital Expenditure | $-211,000 | $-56,000 | $-545,000 | $-1,800,416 |
| Investing Cash Flow | $-21,966,000 | $19,294,000 | $-20,498,000 | $11,709,450 |
| Cash Flow From Continuing Investing Activities | $-21,966,000 | $19,294,000 | $-20,498,000 | $11,709,450 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $142,087,000 | $31,937,000 | $52,581,000 | $41,733,474 |
| Financing Cash Flow | $142,087,000 | $31,937,000 | $52,581,000 | $41,448,700 |
| Cash Flow From Continuing Financing Activities | $142,087,000 | $31,937,000 | $52,581,000 | $41,448,700 |
| Net Common Stock Issuance | $142,087,000 | $31,937,000 | $52,581,000 | $41,733,474 |
| Common Stock Issuance | $142,087,000 | $31,937,000 | $52,581,000 | $41,733,474 |
| Other | ||||
| Income Tax Paid Supplemental Data | $433,000 | $801,000 | $0 | - |
| End Cash Position | $121,330,000 | $68,789,000 | $66,271,000 | $99,248,252 |
| Beginning Cash Position | $68,789,000 | $66,271,000 | $99,351,000 | $37,046,185 |
| Effect Of Exchange Rate Changes | $60,000 | $749,000 | $-8,119,000 | $-141,712 |
| Changes In Cash | $52,481,000 | $1,769,000 | $-24,961,000 | $62,343,780 |
| Net Investment Purchase And Sale | $-21,755,000 | $19,350,000 | $-19,953,000 | $13,496,369 |
| Sale Of Investment | $117,412,000 | $45,121,000 | $0 | $13,496,369 |
| Purchase Of Investment | $-139,167,000 | $-25,771,000 | $-19,953,000 | $0 |
| Net Intangibles Purchase And Sale | $0 | $0 | $-372,000 | $-31,042 |
| Purchase Of Intangibles | $0 | $0 | $-372,000 | $-31,042 |
| Net PPE Purchase And Sale | $-211,000 | $-56,000 | $-173,000 | $-1,769,374 |
| Purchase Of PPE | $-211,000 | $-56,000 | $-173,000 | $-1,769,374 |
| Change In Working Capital | $-33,023,000 | $-15,244,000 | $-19,397,000 | $52,426,647 |
| Change In Other Working Capital | $-28,786,000 | $-10,323,000 | $-5,443,000 | $11,295,112 |
| Change In Other Current Liabilities | $-165,000 | $-175,000 | $-235,000 | - |
| Change In Other Current Assets | $-1,330,000 | $-1,262,000 | $-5,199,000 | $793,587 |
| Change In Payables And Accrued Expense | $499,000 | $-473,000 | $2,024,000 | $3,245,877 |
| Change In Payable | $499,000 | $-473,000 | $2,024,000 | $3,245,877 |
| Change In Receivables | $-3,241,000 | $-3,011,000 | $-10,544,000 | $37,092,072 |
| Changes In Account Receivables | $-904,000 | $392,000 | $-723,000 | $37,092,072 |
| Other Non Cash Items | $-4,472,000 | $-1,803,000 | $-280,000 | $56,685 |
| Stock Based Compensation | $16,307,000 | $16,274,000 | $12,686,000 | $11,650,066 |
| Deferred Tax | $845,000 | $956,000 | $688,000 | $5,953,249 |
| Deferred Income Tax | $845,000 | $956,000 | $688,000 | $5,953,249 |
| Depreciation Amortization Depletion | $593,000 | $621,000 | $596,000 | $576,295 |
| Depreciation And Amortization | $593,000 | $621,000 | $596,000 | $576,295 |
| Amortization Cash Flow | $257,000 | $252,000 | $217,000 | $21,594 |
| Amortization Of Intangibles | $257,000 | $252,000 | $217,000 | $21,594 |
| Depreciation | $336,000 | $369,000 | $379,000 | $554,701 |
| Net Foreign Currency Exchange Gain Loss | $-2,581,000 | $3,962,000 | $-1,003,000 | $411,639 |
| Net Income From Continuing Operations | $-45,309,000 | $-54,228,000 | $-50,334,000 | $-61,888,952 |
| Repayment Of Debt | - | $-221,659 | $-229,938 | $-284,773 |
| Net Issuance Payments Of Debt | - | $-221,659 | $-229,938 | $-284,773 |
| Net Long Term Debt Issuance | - | $-221,659 | $-229,938 | $-284,773 |
| Long Term Debt Payments | - | $-221,659 | $-229,938 | $-284,773 |
| Interest Received Cfi | - | $1,220,398 | $27,835 | $13,496 |
| Taxes Refund Paid | - | $7,912,203 | $0 | $5,953,249 |
| Sale Of PPE | - | - | $0 | $0 |
| Gain Loss On Sale Of PPE | - | - | $0 | $0 |
Fetched: 2026-02-02